Major Companies in India Graves Disease Market | Insights & Key Players 2026

India Graves Disease Market Overview

According to 6Wresearch, the India Graves disease market is witnessing steady expansion, fueled by a rising clinical emphasis on autoimmune health, improved diagnostic infrastructure, and a growing patient pool requiring long-term thyroid management. The industry is seeing a shift toward more sophisticated monitoring, utilizing high-sensitivity antibody assays and ultrasound imaging to guide treatment plans beyond basic symptom relief. This growth is further supported by the introduction of newer therapeutic modalities, such as monoclonal antibodies for thyroid eye disease.

Competitive Landscape

The competitive landscape of the India Graves disease market is a strategic mix of global pharmaceutical innovators and domestic generic leaders who ensure the affordability of lifelong treatments. Organizations are increasingly focusing on patient-centric digital tools, such as remote hormone monitoring and education programs, to improve treatment adherence and manage the complexities of autoimmune-driven hormonal imbalances.

Leading Players Operating in the India Graves Disease Market are:

1. Abbott Laboratories

A cornerstone of the market, Abbott provides the widely recognized "Thyronorm" range and essential anti-thyroid treatments, making it a household name in Indian endocrine care.

2. GlaxoSmithKline (GSK)

GSK is a prestige leader in the sector, known for its legacy thyroid medications and a strong focus on clinical research for autoimmune-related disorders.

3. Sun Pharmaceutical Industries Ltd.

As India's largest pharmaceutical firm, Sun Pharma offers a comprehensive portfolio of hormone regulators and anti-thyroid generics essential for Graves' management.

4. Cipla Limited

Cipla focuses on making high-quality thyroid treatments accessible and affordable, leveraging its vast distribution network to support patients nationwide.

5. Dr. Reddy's Laboratories Ltd.

A global leader in generics that provides bioequivalent anti-thyroid medications, ensuring patients have access to world-class treatment options locally.

6. Lupin Limited

Known for its strong presence in the chronic disease segment, Lupin manufactures several key formulations used to manage the systemic effects of hyperthyroidism.

7. Pfizer

Pfizer remains a critical provider of high-grade specialized therapies and supports the market through its global expertise in autoimmune innovation.

8. Sanofi

Sanofi contributes to the market through its extensive experience in chronic care and its pipeline of biologics targeting autoimmune pathways.

9. Merck Ltd.

A specialist in science and technology, Merck provides high-quality hormonal therapies and diagnostic reagents for thyroid function testing.

10. Zydus Lifesciences Limited

Zydus maintains a robust internal medicine portfolio, producing essential anti-thyroid tablets used widely in clinical hospital settings.

11. Alkem Laboratories Limited

Alkem leverages its massive retail reach to distribute affordable generic anti-thyroid medications to community pharmacies across India.

12. Macleods Pharmaceuticals Ltd.

A major manufacturer of anti-infective and chronic care medicines, Macleods provides reliable generic alternatives for thyroid disorder management.

13. Glenmark Pharmaceuticals Limited

Glenmark contributes with high-quality dermatology and metabolic products, often addressing the secondary symptoms associated with Graves' disease.

14. Intas Pharmaceuticals Ltd.

A leader in complex generics and biosimilars, Intas is increasingly involved in providing advanced therapeutic options for patients with autoimmune complications.